Hemlibra safely reduces bleeding episodes in people with hemophilia A without inhibitors, per a review study that confirmed ...

Successful trial data in a subset of hemophilia patients has set up Pfizer’s Hympavzi, which was approved eight months ago, for a label expansion ...

Pfizer (PFE) stock in focus as its hemophilia drug Hympavzi succeeds in a Phase 3 trial. Read more here.

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and showing good tolerability.

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% compared to on-demand treatment with bypassing agents in patients with ...

Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors Study demonstrates superiority, showing both statistically significant and clinically ...

Hemophilia B Gene Therapy Sustains Efficacy Over a Decade Later — 13-year follow-up shows stable factor IX expression and low bleeding rates ...

HYMPAVZI has received regulatory approvals in the U.S. and in Europe for eligible patients living with hemophilia A without factor VIII inhibitors, or hemophilia B without factor IX inhibitors.

Pfizer Inc. (PFE) on Thursday said that its therapy Hympavzi demonstrated improvement in bleeding outcomes for adults and adolescents living with hemophilia A or B with inhibitors in a late-stage ...

Officers are using a device that makes bruises show up better, which could improve conviction rates.

(RTTNews) - Pfizer Inc. (PFE) Thursday reported positive topline results from the Phase 3 BASIS study of Hympavzi for adults and adolescents living with hemophilia A or B with inhibitors. The ...